All In MedTech

FDA Clearance Tracker · P190002-S001

Saluda Medical Evoke® SCS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 26, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 26, 2022

Approved

Time to decision

237 days

Received Mar 3, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P190002-S001
Device name
Saluda Medical Evoke® SCS System
Applicant location
Atarmon
Received
Mar 3, 2022
Decided
Oct 26, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P190002

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval to move the current cleanroom facilities located at 14 Mars Rd, Lane Cove, NSW, Australia (Lane Cove) to 5 Eden Park Drive, Macquarie Park, NSW, Australia (Macquarie Park) and approval to duplicate external device production from the current Artarmon facility (407 Pacific Highway, Artarmon, NSW, Australia) to the Macquarie Park facility.

Source documents

Other decisions for Saluda Medical Pty, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.